dezamizumab   

GtoPdb Ligand ID: 8255

Synonyms: GSK-2398852 | GSK2398852
Compound class: Antibody
Comment: Dezamizumab (GSK2398852) is an anti-human serum amyloid P component (anti-SAP) monoclonal antibody, being developed by GlaxoSmithKline as a potential therapy for the rare disease amyloidosis.
No information available.
Summary of Clinical Use
Phase I clinical trial NCT01777243 has completed in patients with systemic amyloidosis to assess treatment with GSK2398852 in combination with CPHPC (GSK2315698, a SAP depleting chemical [1]).
Mechanism Of Action and Pharmacodynamic Effects
Amyloidosis is a rare disease that results from accumulation of misfolded proteins, or amyloids. SAP stabilises amyloid fibrils and protects them from proteolytic breakdown [3]. and plays a role in the pathogenesis of systemic amyloidosis [2]. Antibodies against SAP are reported to effectively clear visceral amyloid deposits in mice by inducing a potent, complement dependent, macrophage-derived giant cell reaction [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01777243 A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis Phase 1 Interventional GlaxoSmithKline